Evidence map›Paper›PMID 35058971›Full record

ArticleFrontiers in genetics2021

Whole Genome Assembly of Human Papillomavirus by Nanopore Long-Read Sequencing.

Shuaibing Yang, Qianqian Zhao, Lihua Tang, Zejia Chen, Zhaoting Wu, Kaixin Li, Ruoru Lin, Yang Chen, Danlin Ou, Li Zhou and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Shuaibing YangLaboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, China.
Qianqian ZhaoComputational Systems Biology Lab, Department of Bioinformatics, Shantou University Medical College, Shantou, China.
Lihua TangDepartment of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
Zejia ChenDepartment of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
Zhaoting WuDepartment of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
Kaixin LiUndergraduate Program of Innovation and Entrepreneurship, Shantou University Medical College, Shantou, China.
Ruoru LinUndergraduate Program of Innovation and Entrepreneurship, Shantou University Medical College, Shantou, China.
Yang ChenUndergraduate Program of Innovation and Entrepreneurship, Shantou University Medical College, Shantou, China.
Danlin OuUndergraduate Program of Innovation and Entrepreneurship, Shantou University Medical College, Shantou, China.
Li ZhouDepartment of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
Jianzhen XuComputational Systems Biology Lab, Department of Bioinformatics, Shantou University Medical College, Shantou, China.
Qingsong QinLaboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, China.
Shantou University · CNShantou University Medical College · CNCancer Hospital of Shantou University Medical College · CNKey Laboratory of Guangdong Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) is a causal agent for most cervical cancers. The physical status of the HPV genome in these cancers could be episomal, integrated, or both. HPV integration could serve as a biomarker for clinical diagnosis, treatment, and prognosis. Although whole-genome sequencing by next-generation sequencing (NGS) technologies, such as the Illumina sequencing platform, have been used for detecting integrated HPV genome in cervical cancer, it faces challenges of analyzing long repeats and translocated sequences. In contrast, Oxford nanopore sequencing technology can generate ultra-long reads, which could be a very useful tool for determining HPV genome sequence and its physical status in cervical cancer. As a proof of concept, in this study, we completed whole genome sequencing from a cervical cancer tissue and a CaSki cell line with Oxford Nanopore Technologies. From the cervical cancer tissue, a 7,894 bp-long HPV35 genomic sequence was assembled from 678 reads at 97-fold coverage of HPV genome, sharing 99.96% identity with the HPV sequence obtained by Sanger sequencing. A 7904 bp-long HPV16 genomic sequence was assembled from data generated from the CaSki cell line at 3857-fold coverage, sharing 99.99% identity with the reference genome (NCBI: U89348). Intriguingly, long reads generated by nanopore sequencing directly revealed chimeric cellular-viral sequences and concatemeric genomic sequences, leading to the discovery of 448 unique integration breakpoints in the CaSki cell line and 60 breakpoints in the cervical cancer sample. Taken together, nanopore sequencing is a unique tool to identify HPV sequences and would shed light on the physical status of HPV genome in its associated cancers.

Indexed as

cervical cancerepisomal genomeHPVintegrationnanopore sequencing

Identifiers

PMID35058971
PMCPMC8764290
OpenAlexW4206409973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.